Key result
Lysophosphatidic acid rapidly and dose-dependently inhibited CNP-dependent cGMP elevations in NIH3T3 fibroblasts, with an IC50 of approximately 3.0 microM.
Population
NIH3T3 fibroblasts
Design
Preclinical
Authors
Loading...
Does not inform clinical practice; leaves open LPA-NPR-B interactions in cardiovascular physiology.
Lysophosphatidic acid represses NPR-B guanylyl cyclase activity, revealing a novel heterologous desensitization pathway for the CNP/NPR-B/cGMP signaling axis.
Abbey et al. (2002) studied this question. Lysophosphatidic acid (LPA) was evaluated on CNP-dependent cGMP elevations. Lysophosphatidic acid rapidly and dose-dependently inhibited CNP-dependent cGMP elevations in NIH3T3 fibroblasts, with an IC50 of approximately 3.0 microM.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: